We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial
J. Clin. Oncol 2023 Feb 13;[EPub Ahead of Print], PA Ascierto, EJ Lipson, R Dummer, J Larkin, GV Long, RE Sanborn, V Chiarion-Sileni, B Dréno, S Dalle, D Schadendorf, MK Callahan, M Nyakas, V Atkinson, CA Gomez-Roca, N Yamazaki, HA Tawbi, N Sarkis, D Warad, S Dolfi, P Mitra, S Suryawanshi, JJ Grob